Clinical Trial Update: A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033) [Phase 3]

View source ↗

Summary

Phase 3 clinical study evaluating belzutifan and zanzalintinib in recurrent renal cell carcinoma after adjuvant therapy is in recruitment.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Belzutifan (belzutifan)
• Zanzalintinib (Zanzalintinib)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Renal Cell Carcinoma | Phase 3 | Status: RECRUITING